Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer

Novartis AG NVS released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Radioligand therapy, or radionuclide or radiopharmaceutical therapy, is a targeted cancer treatment that delivers radiation directly to cancer cells. Radioligand therapy's precision helps limit damage to healthy, surrounding tissue. 

The study met its primary endpoint of improvement in progression-free survival (PFS) and the key secondary endpoint of objective response rate (ORR) in patients who received first-line treatment with Lutathera in combination with long-acting octreotide versus high-dose long-acting octreotide alone.

No new or unexpected safety findings were observed in the study.

Also Read: Novartis' Prostate Cancer Therapy Hit By Supply Crunch, Seeks To Ramp Up Production To Ease Supply Issues.

NETs are a type of cancer originating in neuroendocrine cells throughout the body and are commonly considered slow-growing malignancies. 

With these results, NETTER-2 is Lutathera's second Phase 3 trial, showing clinically meaningful results for patients. 

The approval of Lutathera was originally based on the pivotal NETTER-1 trial, which demonstrated highly significant and clinically meaningful PFS prolongation for patients treated with Lutathera in combination with long-acting octreotide versus high-dose (60 mg) long-acting octreotide for SSTR-positive, inoperable midgut neuroendocrine tumors (NETs) who were progressing despite standard treatment.

 Morgan Stanley analyst Vincent Meunier upgrades Novartis from Underweight to Equal-Weight.

Price Action: NVS shares closed at $101.14 on Friday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLarge CapNewsHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!